Cardiac transplantation for end-stage XXXX : the Mayo Clinic experience. Mayo Cardiothoracic Transplant Team.

@entity1 @entity3886 @entity5512 @entity299 @entity1817 @entity849 @entity4924 @entity118 @entity1121 @entity1168 @entity204 @entity4297
OBJECTIVE: To review the outcome of cardiac transplantation undertaken in @entity1 with @entity4297 . MATERIAL AND METHODS: Between November 1991 and March 1998 at our institution, cardiac transplantation was performed in 16 @entity1 with @entity299 (age range, 3 to 57 years; mean, 26.1). Preoperative diagnoses included univentricular heart (N = 4); @entity3886 (N = 3); @entity4924 (N = 2); tetralogy of Fallot (N = 2); levotransposition (N = 2); @entity5512 , corrected transposition, ventricular and @entity118 , and @entity849 (N = 1); double-outlet right ventricle (N = 1); and @entity1121 (N = 1). All @entity1 had undergone from one to five previous palliative operations. RESULTS: Four @entity1 required permanent pacemaker implantation during the first month postoperatively because of @entity1168 ; more than 2 years later, another @entity1 required a permanent pacemaker because of @entity1817 . In addition, one @entity1 had an automatic implantable cardioverter-defibrillator. Three @entity1 required reconstruction of cardiovascular structures with use of prosthetic material (Teflon patches or donor tissue) at the time of cardiac transplantation. Actuarial 1-, 2-, and 5-year survival was 86.2 +/- 9.1%. During the first year after transplantation, two @entity204 occurred--one at 41 days of putative vascular rejection and the second at 60 days of severe cellular rejection. All other @entity1 are alive and functionally rehabilitated; the mean follow-up period has been 26.1 months (range, 2 to 89.6). CONCLUSION: Cardiac transplantation for @entity1 with @entity299 can be accomplished with a low perioperative mortality and an excellent medium-term survival despite the challenges presented by the technical difficulties during invasive diagnostic procedures and at operation and the need for adherence to long-term multiple-drug therapy in this @entity1 population.
